GENETICALLY ENGINEERED WHEAT
Could research related to genetically engineered wheat lead to relevant
results for the gluten-free community? While at present no genetically
engineered wheat is commercially grown in this country, research in this
field has taken place, and it includes some interesting findings.
Researchers from the U.S. and Spain published a study earlier this year
in which they developed a low-gluten wheat. It was demonstrated in this
study that the technology used could reduce the amount of certain
gliadins in the wheat kernel, thereby providing a type of wheat which
would have reduced immunoreactivity for people who are sensitive to
gluten. It is unknown where future research could lead, but this is
certainly an interesting prospect.
Reference
Sanchez-Leon S, et. al. Low-gluten, non-transgenic wheat engineered with CRISPR/Cas9. Plant Biotechnol J.
2017 Sep 18. Doi: 10.1111/pbi.12837 [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/?term=Low-gluten%2C+nontransgenic+wheat+engineered+withCRISPR%2FCas9
LÄHDE: https://www.gluten.org/hot-topics-december-2017/
söndag 7 januari 2018
ICDS 2017. 17. symposium. Intia New Delhi
http://www.icds2017india.com/
Abstraktien aihepiirit:
Sitaatti kutsusta ennen viime syksyn keliakiakonferenssia:
Abstraktien aihepiirit:
ABSTRACT TOPICS & SUB TOPICS
- Epidemiology
- Pathogenesis
- Genetics and Functional Genomics
- Diagnosis and Clinical Presentation
- Pediatric celiace disease
- Refractory celiac disease
- Treatment
- Non- celiac gluten sensitivity
- Miscellaneous
Sitaatti kutsusta ennen viime syksyn keliakiakonferenssia:
Welcome to 17th International Celiac Disease Symposium in New Delhi,
India from 8th to 10th September 2017
After being well recognized in Europe and America, celiac disease is now getting
recognized in Asian countries. It is predicted that the number of patients with
celiac disease in Asia may surpass the numbers present in rest of the world.
Celiac disease is now at the center-stage of the scientific world. The past decade
has been very exciting and productive in terms of diagnostics and understanding
the biology of celiac disease. While gluten-free diet is the best mode of treatment,
many other targets for control of the immune-pathogenesis of celiac disease are
now actively explored, some of them have reached even phase 2 and phase 3 clinical
trials. A lot really happens in the science of celiac disease every year.
International Celiac Disease Symposium is best-known meeting for celiac disease
and it involves clinical scientists, basic scientists, nutritionists, patient forums
and the industry to discuss and explore the best ways to address the challenges
faced by patients with celiac disease. We feel honored and privileged to announce
the dates for the 17th ICDS, which will be held for the first time in Asia between
September 8-10, 2017.
The local organizing committee, together with the international advisory committee
is charting out the contemporary program for the scientific forum, clinical forum
and the patient forum. ICDS 2017 will have keynote lectures, theme based symposia
and debates. There will be sessions reflecting joint interests and needs of scientists,
clinicians, nutritionists and patients. ICDS 2017 will have top line speakers from
all over the globe. We expect delegates from all over the globe including from Asia,
a new host for celiac disease.
I request you to join us in this endeavour and make good of this opportunity and
also enlighten the group sharing your thoughts for the benefit of all. We believe
that this congress is an excellent opportunity for you to gain exposure, as we plan
to webcast the proceedings of this meeting.
Should you have questions or need more information, please contact Ms. Anubha Sharma
at secretariat@icds2017india.com
We look forward to welcoming you to India.
Keliakiakonferenssin kirja 1998
Tampereen konferenssiin osallistujille annettiin kirja Changing Features of Coeliac Disease.
Sen olivat toimittaneet Susanna Lohiniemi, Pekka Collin ja Markku Mäki.
konferensseja on sen jälkeen ollut eri puolilla maailmaa useankin kerran ja joka kerta on uusi kirja tarjolla uusista abstrakteista ja löydöistä. Tässä kirjoitan vuoden 1998 kirjan sisällisluettelon muistiin:
Mäki M. , Changing Features if Coeliac of Coeliac Disease , page 1.
Troncone R., Maurano F., Iovine G., Petrone E., Paparo F., Diagnostic Criteria for Coeliac Disease, page 7.
Reunala T., Dermatitis Herpetiformis from Gut to Skin, page 13.
Holm K., Markers of Coeliac Disease Latency, page 19.
Wieser H., Prolamins in Cereals, page 25.
Janssen F.W., Codex Standard for Gluten Free Products, page31.
Deustch H., Food Legislation and Contamination,page 37.
Kumar P, J., Dietary Compliance and Coeliac Disease, page 45.
Mäki M., To Screen or not to Screen for Coeliac Disease, page 51.
Holmes G. K. T., Malignancy in Coeliac Disease, page 55.
Valdimarsson T., Bone and Calcium Disturbances in Coeliac Disease, page 61.
Ventura A., Coeliac Disease and Autoimmunity, page 67.
Lohiniemi S., Mustalahti K., Collin P., Mäki M.,Measuring Quality of Life in Coeliac Disease Patients, page 73.
Greco L., Evolution of Coeliac Disease.page 79.
Hallert C., The Epidemiology of Coeliac Disease: a Continuous Enigma, page 83.
Collin P., Kaukinen K., Associated Disorders in Coeliac Disease, page 89.
Mäki M., Kaukinen K., Holm K., Collin P., Treatment of Coeliac Patiens with Oats and Wheat Starch. page 93.
Catassi8 C., Rätsch IM., Fabiani E., D´Angelo G., Santinelli A., Bearzi I., Coppa G.V., Low Level Gluten Consumption in Coeliac Childrfen, page 97.
Feghery C., Srinivasan U., Carolan J., Jackson J., Jones E., Weir D.G., O´Farrely C., Oats Challenge in Vivo Does Not Activate Coeliac Disease as Determined by Immunohistological markers, page 103.
Vogelsang H., Granditsch G., Deutsch H., Oats and Wheat Starch in the Diet of Coeliac Patients..
Abstracts 113
Short oral presentations A1- A15 , page 115.
Epidemiology A15- A23, page 122.
Clinics A24- A46, page 126.
Gluten-free diet and cereals A47- A62, page 138.
Associated diseases and complaints A63- A73, page 146.
Serology, page 151.
Genetics and immunology , page 160.
Author index , page 168. Aubajub 444 kirjoittajaa.
Sen olivat toimittaneet Susanna Lohiniemi, Pekka Collin ja Markku Mäki.
konferensseja on sen jälkeen ollut eri puolilla maailmaa useankin kerran ja joka kerta on uusi kirja tarjolla uusista abstrakteista ja löydöistä. Tässä kirjoitan vuoden 1998 kirjan sisällisluettelon muistiin:
Mäki M. , Changing Features if Coeliac of Coeliac Disease , page 1.
Troncone R., Maurano F., Iovine G., Petrone E., Paparo F., Diagnostic Criteria for Coeliac Disease, page 7.
Reunala T., Dermatitis Herpetiformis from Gut to Skin, page 13.
Holm K., Markers of Coeliac Disease Latency, page 19.
Wieser H., Prolamins in Cereals, page 25.
Janssen F.W., Codex Standard for Gluten Free Products, page31.
Deustch H., Food Legislation and Contamination,page 37.
Kumar P, J., Dietary Compliance and Coeliac Disease, page 45.
Mäki M., To Screen or not to Screen for Coeliac Disease, page 51.
Holmes G. K. T., Malignancy in Coeliac Disease, page 55.
Valdimarsson T., Bone and Calcium Disturbances in Coeliac Disease, page 61.
Ventura A., Coeliac Disease and Autoimmunity, page 67.
Lohiniemi S., Mustalahti K., Collin P., Mäki M.,Measuring Quality of Life in Coeliac Disease Patients, page 73.
Greco L., Evolution of Coeliac Disease.page 79.
Hallert C., The Epidemiology of Coeliac Disease: a Continuous Enigma, page 83.
Collin P., Kaukinen K., Associated Disorders in Coeliac Disease, page 89.
Mäki M., Kaukinen K., Holm K., Collin P., Treatment of Coeliac Patiens with Oats and Wheat Starch. page 93.
Catassi8 C., Rätsch IM., Fabiani E., D´Angelo G., Santinelli A., Bearzi I., Coppa G.V., Low Level Gluten Consumption in Coeliac Childrfen, page 97.
Feghery C., Srinivasan U., Carolan J., Jackson J., Jones E., Weir D.G., O´Farrely C., Oats Challenge in Vivo Does Not Activate Coeliac Disease as Determined by Immunohistological markers, page 103.
Vogelsang H., Granditsch G., Deutsch H., Oats and Wheat Starch in the Diet of Coeliac Patients..
Abstracts 113
Short oral presentations A1- A15 , page 115.
Epidemiology A15- A23, page 122.
Clinics A24- A46, page 126.
Gluten-free diet and cereals A47- A62, page 138.
Associated diseases and complaints A63- A73, page 146.
Serology, page 151.
Genetics and immunology , page 160.
Author index , page 168. Aubajub 444 kirjoittajaa.
fredag 5 januari 2018
Lane-Hamilton syndroma
https://www.ncbi.nlm.nih.gov/pubmed/21947219
Eur J Pediatr. 2011 Dec;170(12):1597-602. doi: 10.1007/s00431-011-1568-5. Epub 2011 Sep 23.
Lane-Hamilton syndrome: case report and review of the literature.
Abstract
We
report a case of a three-and-a-half-year-old boy, who presented with
poor general condition, stunted growth, had the presence of nail
clubbing, persistent cough and frequent diarrhoea. Persistent iron
deficiency anaemia without signs of haemolysis suggested Lane-Hamilton
syndrome (LHS) which is or/is an extremely rare combination of
idiopathic pulmonary haemosiderosis (IPH) and celiac disease (CD),
although both diseases are immunologically mediated and the pathogenetic
link between them is not clear. We have now 3 years of follow-up on
gluten-free diet (GFD), resulting in a gradual recovery of the abnormal
laboratory results in combination with an improving growth. Clinically,
he is asymptomatic without any additional treatment. Our case
illustrates that CD should be specifically looked for in patients with
IPH, especially those in whom the severity of anaemia is
disproportionate to the IPH symptoms. Both diseases may benefit from a
GFD.
- PMID:
- 21947219
- DOI:
- 10.1007/s00431-011-1568-5
- [Indexed for MEDLINE]
Tapaus pulmonaari hemosideroosi
https://www.ncbi.nlm.nih.gov/pubmed/27981314
Result Filters
J Gastrointestin Liver Dis. 2016 Dec;25(4):555-558. doi: 10.15403/jgld.2014.1121.254.cut.
Severe Alveolar Hemorrhage - What's in it for the Gastroenterologist?
Abstract
BACKGROUND:
Alveolar hemorrhage is a potentially life-threatening condition which is usually managed by the pulmonologist. When considering its etiology, there is a rare association that sets the disease into the hands of the gastroenterologist.CASE PRESENTATION:
We report the case of a 48 year-old female who was admitted to the intensive care unit for severe anemia and hemoptysis. On imaging, diffuse pulmonary infiltrates suggestive of alveolar hemorrhage were detected and a diagnosis of pulmonary hemosiderosis was made. She received cortisone therapy and hematologic correction of anemia, with slow recovery. In search of an etiology for the pulmonary hemosiderosis, an extensive workup was done, and celiac disease specific serology was found positive. After confirmation of celiac disease by biopsy, a diagnosis of Lane-Hamilton syndrome was established. The patient was recommended a gluten-free diet and at 6 months follow-up, resolution of anemia and pulmonary infiltrates were observed.CONCLUSION:
Although the association is rare, celiac disease should be considered in a patient with idiopathic pulmonary hemosiderosis. In our case, severe anemia and alveolar infiltrates markedly improved with glucocorticoids and gluten-free diet.- PMID:
- 27981314
- [Indexed for MEDLINE]
onsdag 22 november 2017
Ranskalaiset perunat uunivuoan pohjana . Näkökohta K-vitamiini.
Peruna sinänsä antaa hyvää proteiinia 2%, sienistäkin saa hieman proteiinia, samoin juustosta.
(Tällä kertaa tarvitsin kunnolla kalsiumia ja K-vitamiinia koska olin menossa hammaslääkäriin) .
brysselinkaali, Ruusukaali 220 ug K1 vitamiinia /100 g. Tällainen 550 gramman pakkaus antaa siis 1210 ug K1 vitamiinia ja muutamien päivien aikana käytettynä kyllä täyttää kaikki K1 hetkelliset vitamiinitarpeet, jopa luuston muodostukselle tarvittavat peptidit saavat funktionaalisuutensa eikä vain hyytymistekijät ja luontaisen negatiivisen koagulaatiokontrollin tekijät. Muistakin vihanneksista tässä vuoassa tulee vähäisen K1 vitamiinia..Juusto taas antaa jotain menakinonia K2-vitamiinia, jota joistain animaalisista lähteistä saa.
Paistetusta perunasta saa miltei 7 ug K1 vitamiinia sadalta grammalta. Joisasin paistinrasvoissa on K1 vitamiinia, ei kaikissa.
Esim rypsiöljy, jota käytän, antaa 150 ug 100 äljymillissä, mutta eihän näin suurta määrää paistoon tarvita. Joka tapauksessa yksi 1 ug painokiloa kohti nyt öljystäkin tulee, mikä on K1 vitamiinin minimisaanti jos aspektina on veren hyytyminen. Muut aspektit, muut vaatimukset K1 vitamiinin saannista ovat suurempaa ug luokkaa, kuten luun muodostuksen vaatimukdet ja antiaterogeneesi ja myeliinin osatekijöiden muodostus.muta niitä ei ole määritelty tarkemmin, koska vitaalia on K1 saanti ja joissaint taudeissa jopa K1-vitamiinin saannin rajoitus, koska K1 vitamiini kaikista funktioistaan ensimmäisenöä tekee veren hyytymistekijät funktionaaliseksi, evolutionaalisista syistä johtuen_ Ihmiskunnan tuhansien vuosien historiassa vuototaipumus on suurempi vaara kuin tulppataipumus. Jälkimmäinen tuleev asta hyvinvoinnin mukana dominoivaksi asiaksi,. Tässä onkin siten kuin avaruuslaivoissa tapahtuvat asioiten kytkeytymiset toisiinsa aika tarkkaa säätelyä että päästään yli vaarallisen vaiheen. Jos K1 vitamiini joudutaan rajoittamaan on tilanne lähinnä sama kuin kaksi avaruusalusta kiertävät omalla radallaan eivätkä näe tarvetta kommunikoida tai tehdä pintakontaktia ja pärjäilevät hyvin omissa orbitaaleillaan. Sellainen antikoagulanttistrategia on vitaalisti hengenpelastava toimenpide. kunnes K1-vitamiinien ja K2 vitamiinien saanti on asennettu runsaaksi aivan varhaisesta laopsuudesta, jolloin monia ongelmia ei tule olemaan.
https://fi.wikipedia.org/wiki/Ruusukaali
Muistiin 22.11. 2017
Prenumerera på:
Inlägg (Atom)